RBC Says Tekmira Pharmaceuticals Corporation (TKMR) Hype Missing The Point

As the roller coaster ride that is the Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) stock continues, the Royal Bank of Canada (NYSE:RY) (TSE:RY) is out with a new report that seems to suggest investors are missing the point. Tekmira’s Hepatitis B cure is the real value The RBC research report shouts the headline that while the Ebola scare, and Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)’s cure for the health epidemic, is in the headlines, it is the firm’s Hepatitis B cure that is the real value. The report says that even given the near 80 percent rise then subsequent retracement, Tekmira remains undervalued due to…